Douglas V. Faller

Also affiliated with Celsion (United States), Immersion (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer”.

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Blood Advances(2023)10.1182/bloodadvances.2023010330

N/A

1.0DataRank · unranked

48 citations

Önder Alpdoğan, Robert A. Baiocchi, Jonathan E. Brammer, Tatyana Feldman, Marcelo Capra +15 more

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

The Journal of Clinical Pharmacology(2021)10.1002/jcph.1958

N/A

0.469DataRank · unranked

8 citations

Diane R. Mould, Ying Yuan, Elizabeth Fox, Emily Greengard, Douglas V. Faller +2 more

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.578

N/A

0.399DataRank · unranked

12 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Mark S. Reed, Melanie K Bergman +21 more

105P Immune biomarker analysis of the OVATION-2 trial, a randomized phase I/II study of IL-12 gene therapy IMNN-001 in combination with neo/adjuvant chemotherapy (NACT) in newly-diagnosed advanced epithelial ovarian cancer (EOC)

ESMO Open(2025)10.1016/j.esmoop.2025.105233

N/A

0DataRank · unranked

1 citations

Debra L. Richardson, Andrea R. Hagemann, Robert W. Holloway, Bhavana Pothuri, Jennifer Scalici +14 more